1. Basic Principles
Currently, most mRNA drug products on the market utilize delivery systems represented by LNP (Lipid Nanoparticle), such as the commercially available Pfizer/BioNTech and Moderna COVID-19 mRNA vaccines.
Healrna's proprietary Cell-Like System (CLS) delivery technology is a unique platform technology with independent intellectual property rights. Its structure is inspired by the protein-phospholipid layer design of biomimetic cell membranes, making it particularly suitable for the targeted delivery of mRNA drugs.
2. Technical advantages
●Healrna’s CLS (Cell-like System) dilivery
|
By altering the types and structures of the protein-like components, targeted delivery to specific tissues or organs can be achieved. For instance, HealRNA’s spleen-targeting formulation (CLS-Spleen) has demonstrated a 50-fold higher targeting efficiency compared to traditional lipid nanoparticles (LNP) in animal studies. |
|
The CLS carrier can efficiently encapsulate nucleic acid drugs and achieve rapid intracellular release, thereby enhancing drug transfection efficiency. In tumor vaccine applications, the CD8+ T cell response induced by the CLS-Tumor carrier is several times greater than that of traditional LNP carriers. |
|
Composed primarily of proteins, the CLS delivery system exhibits fewer side effects and lower immunogenicity compared to LNP delivery technology, making it more suitable for long-term therapeutic applications. |
|
The formulation is stable and can be freeze-dried for storage and transportation at room temperature. |
|
An independently developed protein-like structure library with its own intellectual property rights, and the patent IP can be exported overseas. |
●Internationally patented LNP delivery system with proprietary technology
|
|
|
|
|
|
|
|
